Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Ferguson, Stuart G ^a   Walters, Julia A E ^a   Lu, Wenying ^a   Wells, Gudrun P ^a   Schüz, Natalie ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Nicotine patch; Pre quit treatment; Smoking reduction; Varenicline

Indexed keywords

NICOTINE GUM; NICOTINIC AGENT; VARENICLINE;

AFFECT; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SMARTPHONE; SMOKING CESSATION; SOCIAL ENVIRONMENT; SUBSTANCE WITHDRAWAL SYNDROME;

AFFECT; FEMALE; HUMANS; MALE; NICOTINIC AGONISTS; RESEARCH DESIGN; SMARTPHONE; SMOKING CESSATION; SOCIAL ENVIRONMENT; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84954374730     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-2596-2     Document Type: Article

References (36)

1. Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, et al. Global statistics on addictive behaviours: 2014 status report. Addiction. 2015;110(6):904-19. doi: 10.1111/add.12899.
2. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-92. doi: 10.1001/jama.2013.284692.
3. Lebrun-Harris LA, Fiore MC, Tomoyasu N, Ngo-Metzger Q. Cigarette smoking, desire to quit, and tobacco-related counseling among patients at adult health centers. Am J Public Health. 2015;105(1):180-8. doi: 10.2105/AJPH.2013.301691.
4. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102-11. doi: 10.1016/j.amepre.2007.09.033.
5. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29-38.
6. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329. doi: 10.1002/14651858.CD009329.pub2.
7. Fiore M. United States. Tobacco use and dependence guideline panel. Treating tobacco use and dependence: 2008 update, Clinical practice guideline. 2008 updateth ed. Rockville: Dept. of Health and Human Services, Public Health Service; 2008.
8. Jha P. Chaloupka F.J. Curbing the epidemic: Governments and the economics of tobacco control. the World Bank Tob Control 1999 8:2 196-201.
9. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166(15):1553-9. doi: 10.1001/archinte.166.15.1553.
10. Levin ED, Slade S, Johnson M, Petro A, Horton K, Williams P, et al. Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats. Eur J Pharmacol. 2008;600(1-3):93-7. doi: 10.1016/j.ejphar.2008.10.016.
11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63. doi: 10.1001/jama.296.1.56.
12. Ferguson SG, Gitchell JG, Shiffman S. Continuing to wear nicotine patches after smoking lapses promotes recovery of abstinence. Addiction. 2012;107(7):1349-53. doi: 10.1111/j.1360-0443.2012.03801.x.
13. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers. Clin Ther. 2009;31(9):1957-65. doi: 10.1016/j.clinthera.2009.08.029.
14. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl). 2011;214(3):579-92. doi: 10.1007/s00213-010-2069-3.
15. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction. 2008;103(4):557-63. doi: 10.1111/j.1360-0443.2008.02138.x.
16. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. doi: 10.1002/14651858.CD000146.pub4.
17. Foulds J, Stapleton J, Feyerabend C, Vesey C, Jarvis M, Russell MA. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology (Berl). 1992;106(3):421-7.
18. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol. 1994;14(1):41-9.
19. Schuz N, Ferguson SG. An exploratory examination of the mechanisms through which pre-quit patch use aids smoking cessation. Psychopharmacology (Berl). 2014;231(13):2603-9. doi: 10.1007/s00213-013-3430-0.
20. Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl). 2006;184(3-4):608-18. doi: 10.1007/s00213-005-0175-4.
21. Ferguson SG, Shiffman S. Using the methods of ecological momentary assessment in substance dependence research - smoking cessation as a case study. Subst Use Misuse. 2011;46(1):87-95. doi: 10.3109/10826084.2011.521399.
22. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1-32.
23. Hammersley R. A digest of memory phenomena for addiction research. Addiction. 1994;89(3):283-93.
24. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine Tob Res. 2011;13(10):955-64. doi: 10.1093/ntr/ntr103.
25. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171(11):1199-205. doi: 10.1176/appi.ajp.2014.13050595.
26. Lerman C, Schnoll RA, Hawk Jr LW, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131-8. doi: 10.1016/S2213-2600(14)70294-2.
27. Frandsen M, Walters J, Ferguson SG. Exploring the viability of using online social media advertising as a recruitment method for smoking cessation clinical trials. Nicotine Tob Res. 2014;16(2):247-51. doi: 10.1093/ntr/ntt157.
28. Zwar N, Richmond R, Borland R, Peters M, Litt J, Bell J, et al. Supporting smoking cessation: a guide for health professionals. Melbourne: The Royal Australian College of General Practitioners. 2011.
29. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119-27.
30. Shiffman S, Sayette MA. Validation of the nicotine dependence syndrome scale (NDSS): a criterion-group design contrasting chippers and regular smokers. Drug Alcohol Depend. 2005;79(1):45-52. doi: 10.1016/j.drugalcdep.2004.12.009.
31. Saunders JB, Aasland OG, Babor TF, Delafuente JR, Grant M. Development of the Alcohol-Use Disorders Identification Test (Audit) - Who Collaborative Project on Early Detection of Persons with Harmful Alcohol-Consumption.2. Addiction. 1993;88(6):791-804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
32. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
33. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32(5):912-23. doi: 10.1016/j.addbeh.2006.06.028.
34. Ferguson SG, Shiffman S. Effect of high-dose nicotine patch on the characteristics of lapse episodes. Health Psychol. 2010;29(4):358-66. doi: 10.1037/a0019367.
35. Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74(2):276-85. doi: 10.1037/0022-006x.74.2.276.
36. Shastri MD, Lu WY, Ferguson SG, Narkowicz CK, Davies NW, Jacobson GA. Determination of cotinine, 3 ′-hydroxycotinine, and their glucuronides in urine by ultra-high performance liquid chromatography. Anal Lett. 2015;48(8):1217-33. doi: 10.1080/00032719.2014.979363.